Platelet mitochondrial dysfunction and mitochondria-targeted quinone-and hydroquinone-derivatives: Review on new strategy of antiplatelet activity.
Platelet mitochondrial dysfunction has been identified in different diseases. Platelet mitochondrial dysfunction favors platelet activation with a considerable increase in oxidative stress, which is implicated in platelet non-responsiveness to current antiplatelet therapy. The inhibition of platelet mitochondrial dysfunction could potentially be used as a new strategy for the development of antiplatelet activity drugs. In this context, we described quinone and hydroquinone derivatives and mitochondrially targeted compounds as initial precursors for the synthesis of new antiplatelet agents.